151 related articles for article (PubMed ID: 25940702)
1. Novel harmine derivatives for tumor targeted therapy.
Li S; Wang A; Gu F; Wang Z; Tian C; Qian Z; Tang L; Gu Y
Oncotarget; 2015 Apr; 6(11):8988-9001. PubMed ID: 25940702
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationships of harmine derivatives as potential antitumor agents.
Cao R; Fan W; Guo L; Ma Q; Zhang G; Li J; Chen X; Ren Z; Qiu L
Eur J Med Chem; 2013 Feb; 60():135-43. PubMed ID: 23291116
[TBL] [Abstract][Full Text] [Related]
3. Antitumor and neurotoxic effects of novel harmine derivatives and structure-activity relationship analysis.
Chen Q; Chao R; Chen H; Hou X; Yan H; Zhou S; Peng W; Xu A
Int J Cancer; 2005 May; 114(5):675-82. PubMed ID: 15609303
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of N(9)-substituted harmine derivatives as potential anticancer agents.
Du H; Tian S; Chen J; Gu H; Li N; Wang J
Bioorg Med Chem Lett; 2016 Aug; 26(16):4015-9. PubMed ID: 27397495
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and mechanisms of action of novel harmine derivatives as potential antitumor agents.
Zhang XF; Sun RQ; Jia YF; Chen Q; Tu RF; Li KK; Zhang XD; Du RL; Cao RH
Sci Rep; 2016 Sep; 6():33204. PubMed ID: 27625151
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and cytotoxic activities of 1-benzylidine substituted beta-carboline derivatives.
Cao R; Yi W; Wu Q; Guan X; Feng M; Ma C; Chen Z; Song H; Peng W
Bioorg Med Chem Lett; 2008 Dec; 18(24):6558-61. PubMed ID: 18952426
[TBL] [Abstract][Full Text] [Related]
7. Novel trisubstituted harmine derivatives with original in vitro anticancer activity.
Frédérick R; Bruyère C; Vancraeynest C; Reniers J; Meinguet C; Pochet L; Backlund A; Masereel B; Kiss R; Wouters J
J Med Chem; 2012 Jul; 55(14):6489-501. PubMed ID: 22770529
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, cytotoxic, anti-lipoxygenase and anti-acetylcholinesterase capacities of novel derivatives from harmine.
Filali I; Belkacem MA; Ben Nejma A; Souchard JP; Ben Jannet H; Bouajila J
J Enzyme Inhib Med Chem; 2016; 31(sup1):23-33. PubMed ID: 27028352
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and in vitro and in vivo antitumor activities of novel beta-carboline derivatives.
Cao R; Chen H; Peng W; Ma Y; Hou X; Guan H; Liu X; Xu A
Eur J Med Chem; 2005 Oct; 40(10):991-1001. PubMed ID: 15950325
[TBL] [Abstract][Full Text] [Related]
10. DNA binding properties of 9-substituted harmine derivatives.
Cao R; Peng W; Chen H; Ma Y; Liu X; Hou X; Guan H; Xu A
Biochem Biophys Res Commun; 2005 Dec; 338(3):1557-63. PubMed ID: 16288723
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, acute toxicities, and antitumor effects of novel 9-substituted beta-carboline derivatives.
Cao R; Chen Q; Hou X; Chen H; Guan H; Ma Y; Peng W; Xu A
Bioorg Med Chem; 2004 Sep; 12(17):4613-23. PubMed ID: 15358288
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Biological Evaluation of Harmirins, Novel Harmine-Coumarin Hybrids as Potential Anticancer Agents.
Pavić K; Beus M; Poje G; Uzelac L; Kralj M; Rajić Z
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770906
[TBL] [Abstract][Full Text] [Related]
13. Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
Ishida J; Wang HK; Bastow KF; Hu CQ; Lee KH
Bioorg Med Chem Lett; 1999 Dec; 9(23):3319-24. PubMed ID: 10612592
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of new isoxazoline derivatives from harmine and evaluation of their anti-Alzheimer, anti-cancer and anti-inflammatory activities.
Filali I; Bouajila J; Znati M; Bousejra-El Garah F; Ben Jannet H
J Enzyme Inhib Med Chem; 2015 Jun; 30(3):371-6. PubMed ID: 25068731
[TBL] [Abstract][Full Text] [Related]
15. Complexation with β-cyclodextrin enhances apoptosis-mediated cytotoxic effect of harman in chemoresistant BRAF-mutated melanoma cells.
Ferraz CAA; de Oliveira Júnior RG; de Oliveira AP; Groult H; Beaugeard L; Picot L; de Alencar Filho EB; Almeida JRGDS; Nunes XP
Eur J Pharm Sci; 2020 Jul; 150():105353. PubMed ID: 32334103
[TBL] [Abstract][Full Text] [Related]
16. Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems.
Lala S; Pramanick S; Mukhopadhyay S; Bandyopadhyay S; Basu MK
J Drug Target; 2004 Apr; 12(3):165-75. PubMed ID: 15203896
[TBL] [Abstract][Full Text] [Related]
17. Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro.
Hamsa TP; Kuttan G
Eur J Pharmacol; 2010 Dec; 649(1-3):64-73. PubMed ID: 20858484
[TBL] [Abstract][Full Text] [Related]
18. Interaction of β-carboline alkaloids with RNA.
Nafisi S; Malekabady ZM; Khalilzadeh MA
DNA Cell Biol; 2010 Dec; 29(12):753-61. PubMed ID: 20731607
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of harmine-nitric oxide donor derivatives as potential antitumor agents.
Li Z; Apizi Y; Zhang C; Wang Z; He H; Li X; Zhu Y; Yang J; Xiao L; Wang M
Bioorg Med Chem Lett; 2022 Jun; 65():128698. PubMed ID: 35341920
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological effects of harmine and its derivatives: a review.
Zhang L; Li D; Yu S
Arch Pharm Res; 2020 Dec; 43(12):1259-1275. PubMed ID: 33206346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
